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Background: For years Plasmodium vivax has been considered the cause of benign malaria. Nevertheless, it has
been observed that this parasite can produce a severe disease comparable to Plasmodium falciparum. It has been
suggested that some physiopathogenic processes might be shared by these two species, such as cytoadherence.
Recently, it has been demonstrated that P. vivax-infected erythrocytes (Pv-iEs) have the capacity to adhere to
endothelial cells, in which intercellular adhesion molecule-1 (ICAM-1) seems to be involved in this process.
Methods: Adherence capacity of 21 Colombian isolates, from patients with P. vivax mono-infection to a
microvascular line of human lung endothelium (HMVEC-L) was assessed in static conditions and binding was
evaluated at basal levels or in tumor necrosis factor (TNF) stimulated cells. The adherence specificity for the ICAM-1
receptor was determined through inhibition with an anti-CD54 monoclonal antibody.
Results: The majority of P. vivax isolates, 13 out of 21 (61.9%), adhered to the HMVEC-L cells, but P. vivax adherence
was at least seven times lower when compared to the four P. falciparum isolates. Moreover, HMVEC-L stimulation
with TNF led to an increase of 1.6-fold in P. vivax cytoadhesion, similar to P. falciparum isolates (1.8-fold) at
comparable conditions. Also, blockage of ICAM-1 receptor with specific antibodies showed a significant 50%
adherence reduction.
Conclusions: Plasmodium vivax isolates found in Colombia are also capable of adhering specifically in vitro to lung
endothelial cells, via ICAM-1 cell receptor, both at basal state and after cell stimulation with TNF. Collectively, these
findings reinforce the concept of cytoadherence for P. vivax, but here, to a different endothelial cell line and using
geographical distinct isolates, thus contributing to understanding P. vivax biology.
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ColombiaBackground
It has been estimated that Plasmodium vivax causes
around 80–300 million cases per year, mainly in the
Asian and Latin American regions [1]. For a long time
P. vivax was considered the cause of benign malaria [1].
Nevertheless, it has been observed that this species can
cause severe disease similar to Plasmodium falciparum
and complications caused by P. vivax mono-infection
have been described, such as cerebral malaria with* Correspondence: silviablairt@gmail.com
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distribution, and reproduction in any mediumgeneralized seizures and epileptic status, severe anaemia,
hepatic dysfunction and jaundice, acute lung lesion,
acute respiratory distress syndrome (ARDS) and pul-
monary oedema, shock, splenic rupture, acute renal fail-
ure and acute thrombocytopaenia with or without
bleeding on different body sites [2-9]. Most recently,
goes back to 2008 with the acquisition of P. vivax gen-
omic sequence, it was found that around 80% of the
genes are orthologous and mostly synthenic between the
P. vivax and P. falciparum genomes [10-12]. Taken
together this suggests that P. falciparum malaria pa-
thogenic processes related to cytoadhesion may occur in
P. vivax [13]. Furthermore, studies performed by Ansteyntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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malaria could be caused by sequestration of parasitic
forms within this organ [14]. In this sense, Carvalho
et al. reported that P. vivax has the ability to cytoadhere
ex vivo to human lung endothelial cells (HLEC) and, to
a lesser extent, to placenta cryosections. The adhesion
found was similar in strength to that observed in P. fal-
ciparum, though ten times lower in number [13]. Ac-
cordingly, Chotivanich et al. demonstrated that P. vivax
isolates from Thailand have the ability to adhere to
chondroitin sulphate A (CSA) and to hyaluronic acid
(HA) in placental sections [15-18]. Moreover, in 2012,
Bernabeu et al. reported the participation of vir 14 protein
in the adherence to ICAM-1 receptor on the Chinese
hamster ovary (CHO) cells transfected with human
ICAM-1 (CHO-ICAM-1) cell line [18].
In Colombia, P. vivax continues to cause high impact
on public health, with 83,255 (70.7%) cases in 2010, from
a total of 117,650 reported malaria cases. Severe P. vivax
malaria cases have been described primarily in newborn,
children and pregnant women [9,19,20]. Due to the
emergence of complications caused by P. vivax infection
and its cytoadherence capacity, the purpose of this study
was to determine the adherence capacity of Pv-iEs from
Colombian patients, to human lung endothelial cells




This study was approved by the Faculty of Medicine of the
University of Antioquia’s ethics committee records 012 –
18 June, 2009. All participants agreed to voluntarily donate
their blood samples after signing an informed consent.
Study area and subjects
Up to 8.5 ml of peripheral blood was collected from 21
P. vivax non-complicated malaria patients, diagnosed byFigure 1 Percoll concentration, before and after enrichment 45% Per
1% Giemsa stain of trophozoites, schizonts and gametocytes. 100× objectivthe thick-smear method and confirmed by rapid diag-
nostic test (Bioline SD05FK80) and polymerase chain re-
action (PCR) (to dismiss mixed infections at low levels).
Seven patients, all from different places of the Depart-
ment of Antioquia, were recruited at the University of
Antioquia Malaria Group office in Medellin, and the
remaining 14, at the Nuestra Señora del Carmen Hos-
pital in El Bagre – Bajo Cauca- Department of Antioquia
(7° 35′ 0″ N, 74° 48′ 0″ W). To compare the P. vivax
isolates adhesion, four P. falciparum isolates were adapted
to in vitro culture [21].Isolation and concentration of Plasmodium vivax mature
forms
The methodology described by Carvalho et al. [13] was
followed with few modifications. The initial patient para-
sitaemia was determined by counting the different para-
sitic forms in 200 leucocytes with an 8,000 leukocytes
standard in order to obtain the amount of parasites per
μL. Samples were processed immediately after blood col-
lection [22]. Plasma was removed by centrifugation at
2,500 rpm; for removal of WBC, blood was filtered with a
Whatman CF11 cellulose column, the resultant pellet was
washed three times using RPMI 1640 (Sigma) pH 7.2
medium, and resuspended to a 10% haematocrit. Later,
the Pv-iEs with mature forms (trophozoites, schizonts and
gametocytes) were concentrated and separated from the
young stages (rings) and non-infected erythrocytes. For
this purpose, 5 mL of the 10% erythrocytes suspension
were overlaid on 5 mL of 45% Percoll solution (Sigma
P1644) and then the mixture was centrifuged at
2,500 rpm for 20 min at 4°C. The interphase containing
mature forms was washed three times with RPMI-1640
pH 7.2. Mature stages were observed by thin smears
(Figure 1). The estimated percentage of mature forms
and the number of Pv-iEs per ml was obtained using the
Neubauer chamber count (0.0025 sq mm).coll gradient concentration of the mature stages of P. vivax.
e.
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Plasmodium falciparum FCR3/Gambia strain (donated
by National Institutes of Health- NIH, Laboratory of
Malaria and Vector Research) were cultured following
Trager and Jensen’s method [21]. Mature stages concen-
tration was carried out using 60% Percoll [23].
Isolation and concentration of Plasmodium falciparum
mature forms harvested from infected patients
The four field P. falciparum isolates were adapted to an
in vitro culture and were maintained as described for
FCR3 strain. The mature concentration stages were
obtained with 1% Gelatin flotation (Sigma G2625) [24].
The percentage of mature forms, and the number of P.
falciparum-infected erythrocytes by ml were estimated
using the Neubauer chamber count, as previously de-
scribed [25].
Human lung endothelial cells (HMVEC-L) culture
The HMVEC-L was maintained following the distribu-
tor’s protocol (Lonza CC-2527), in endothelial basal
medium −2 (EBM-2) (CC-3156) supplemented with
endothelial growth medium (EGM-2) MV BulletKit
from Lonza-Clonetics (CC-3202) at 37°C and 5% CO2,
until achieving a 70-90% confluence. The cells were
then treated with Trypsin-EDTA (Lonza) and seeded in
Lab-Tek II 8 wells chambers (Brand-Products).
Plasmodium vivax cytoadherence assay in static
conditions
Cytoadherence assays in static conditions were performed
according to Carvalho et al. [13]. Briefly, HMVEC-L were
seeded in Lab-Tek II chambers (Brand-Products), and
5 × 104 Percoll-enriched parasites per well were incubated
in a total volume of 200 μL cytoadhesion medium (RPMI-
1640, pH: 6.8) at 37°C for one hour in incubator agitation
at 90 rpm (IKA KS 4000 IC Control). Non-adhered para-
sites and non-infected erythrocytes were removed by ex-
tensive washing in cytoadhesion medium. The adhered
parasites were fixed using methanol for 2 min, and stained
with Giemsa 1%. The number of parasites adhered were
counted in a total of 200 HMVEC-L.
ICAM-1 (CD54) expression in HMVEC-L treated with TNF
The ICAM-1 expression in HMVEC-L was induced
by TNF treatment (10 ng/mL; Sigma-Aldrich) for 18–Table 1 Percentage of cytoadherence of Plasmodium vivax iso
Frequency Percentage
P. vivax isolates Adherent 13 61.9
Non-adherent 8 38.1
Total 21 100.0
Total cytoadherence of P. vivax isolates, average parasitaemia and their standard de22 hours. The ICAM-1 expression levels evaluation was
determined in a FACS Canto II flow cytometer (BD Bio-
sciences) using a Mouse Anti-Human CD54 monoclonal
(FITC-Conjugated, Millipore) for 30 min, at 4°C in ap-
proximately 500,000 cells. The fluorescence intensity and
percentage of positive cells for ICAM-1 was analysed in a
minimum of 10,000 events acquired and analysed using
the WinMDI 2.8 program. The adherence specificity to
the ICAM-1 receptor was performed by previous incuba-
tion of HMVEC-L TNF stimulated cells with 10 μg/ml of
anti-human CD54 monoclonal (clone 15,2 Serotec AbD
MCA532) at room temperature for 30 min and then
cytoadherence assay were performed as described.
Statistical analysis
The statistical significance of the performed comparisons
was determined using the Mann–Whitney U test. Calcula-
tions were performed using the IBM-SPSS Statistics 21
program, and the charts with the Prism Software (6.01
version; GraphPad Software). Differences were considered
significant when a p < 0.05.
Results
A total of 21 P. vivax isolates confirmed through PCR
were included. Average parasitaemia was 7,604.7 ± 6,963
parasites/μL. These isolates came from different regions
of Antioquia, mainly from Bajo-Cauca, and presented >60%
mature asexual stages predominance. The average age of
the 21 patients was 28.4 ± 14.1 years and 15 (71.4%) of
them were males. The average parasitaemia of the adher-
ent isolates was 9,461.5 ± 4,280.6 parasites/μL (Table 1).
Thirteen P. vivax isolates (61.9%) presented adherence to
HMVEC-L both at basal state and when cells were stimu-
lated with TNF. The average basal state of Pv-iEs per 200
HMVEC-L was 32.5 ± 19.1; and after TNF stimulation a
1.6-fold increasing (52.1 ± 19.5, p < 0.001) in parasite-
infected erythrocytes was observed (Table 2) (Figure 2A
and B). No significant statistical differences (p > 0.05)
between the parasitaemia averages from adherent and
non-adherent parasites were noticed.
Adherence of four P. falciparum isolates at basal state
was 161.8 ± 196.2 and with TNF stimulation adhesion
reach to 368.7 ± 429.1 (1.8-fold) and the adherence ob-
served in the P. falciparum strain (FCR3) was 201 ± 61
parasite infected erythrocytes and after TNF stimulation
it was 465 ± 498 (Table 2) (Figure 2C).lates
Average parasitaemia parasites/μL (SD) Significance (95%)
9,461.5 (7766.1) 0.122
4,587.5 (4280.6)
viations, significance value 95%.
Table 2 Cytoadherence of Plasmodium vivax and
Plasmodium falciparum isolates in HMVEC-L basal and
stimulated with TNF-α
Adherence (% of inhibition)
Isolate Adherence1 Anti-CD54
P. vivax Basal Stimulated
TNF-α(code)
0.012 19.0 ± 1 27.0 ± 2 ND
0.013 19.5 ± 2.5 39.5 ± 5.5 ND
0.014 10.5 ± 1.5 33.5 ± 3.5 ND
0.015 4.0 ± 1 24.5 ± 2.5 ND
0.017 42.0 ± 4 51.0 ± 16 ND
0.018 28.0 ± 3 52.0 ± 7 31.5 (39.4)
0.019 38.0 ± 9 58.5 ± 6.5 34 (41.9)
0.022 37.0 ± 11 81.5 ± 2.5 36.5 (55.2)
0.024 53.0 ± 6 77.5 ± 10.5 33.5 (56.8)
0.025 28.5 ± 6.5 67.5 ± 3.5 23.5 (56.8)
0.026 55.5 ± 7.5 69.5 ± 11.5 27 (61.2)
0.027 35.5 ± 10.5 47.0 ± 8 42 (10.6)
0.028 22.0 ± 4 48.5 ± 4.5 22 (54.6)
P. falciparum
0.033 58.5 ± 13.4 113 ± 16.9
0.034 17 ± 7.1 53 ± 8.5
0.035 475 ± 38.2 1050 ± 74.9
0.036 97 ± 8.5 259 ± 24
FCR3 201 ± 49.8 465 ± 61
P. vivax and P. falciparum isolates cytoadherence to microvascular line of
human lung endothelium HMVEC-L, from the isolate code 0.018 – 0.028 the
percentage of adherence inhibition is described, compared to endothelial cells
treated with TNF.
1. Average ± standard deviation of Pv-iEs per 200 HMVEC-L.
Figure 2 Cytoadherence of clinical isolates of Plasmodium sp. to hum
Pv-iEs to human lung endothelial cells HMVEC-L. 1% Giemsa stain. C. Cytoadh
and C 40× objective.
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parasite cytoadherence was determined in eight P. vivax
isolates through cytoadherence inhibition assay using
the monoclonal antibody anti-CD54 in TNF stimulated
cells. A 50% cytoadherence reduction was observed in
the average of adhered Pv-iEs/200 HMVEC-L, compared
to cells without antibody anti-CD54, 62.7 ± 19.5 vs. 31.2 ±
8.8 Pv-iEs (Figure 3).
Discussion
Cytoadherence of P. vivax isolates from Colombia was
demonstrated using primary microvascular endothelial
lung cells in static conditions as respiratory distress are
one of the most frequently malaria vivax complication
reported [26-29]. These assays revealed that the majority
of P. vivax isolates, 13 out of 21 (61.9%), adhered to the
lung endothelial cells and stimulation with TNF lead to
a significant increase of 1.6-fold in P. vivax cytoadhe-
rence. Moreover, blockage of ICAM-1 receptor with spe-
cific antibodies showed a 50% significant reduction in
parasite binding, thus demonstrating a P. vivax ability to
adhere to the ICAM-1 receptor. As expected, P. vivax
adherence was at least seven times lower in comparison
to P. falciparum isolates. This latter finding is consistent
with a previous report using Brazilian isolates [13].
The involvement of TNF in malaria pathogenesis has
already been demonstrated in experimental cerebral
malaria model [30]. The TNF released by monocytes in
response to the endothelium damage or in the presence
of soluble factors derived from the parasite such as
glycosyl-phosphatidylinositol (GP-I) and haemozoin, in-
creases ICAM-1 levels expressed in endothelial cells,
and therefore enhances leukocytes and platelets adhe-
sion and parasite sequestration to the endothelium
[30,31]. Moreover, inflammatory co-morbidities, includingan lung endothelial cells HMVEC-L A and B. Cytoadherence of













































Figure 3 Average adherence of Pv-iEs to the ICAM-1
endothelial receptor. 5*104 parasites/well were added to HMVEC-L-TNF,
HMVEC-L-TNF- antiCD54 mAb, or to the basal control HMVEC-L. The
scatter plot shows adherence data is an average of the number of
Pv-iEs/200HMVEC-L; Asterisks indicate statistical significance with
respect to adhesion values, as follows: *0.05 > p > 0.01;
**0.01 > p > 0.001; ***p < 0.001.
De las salas et al. Malaria Journal 2013, 12:347 Page 5 of 6
http://www.malariajournal.com/content/12/1/347bacterial infections, seem to play a key role in P. vivax
clinical complications [3]. Therefore, endothelial cells
were treated with TNF prior to Pv-iEs adhesion as dem-
onstrated. These results suggest that in an ICAM-1
overexpression scenario due to high expression of TNF
allowed P. vivax to improve its adhesion ability. In order
to explore this hypothesis, the ICAM-1 receptor was
blocked using anti-CD54 showing an average reduction
of 50% in the cytoadherence in TNF stimulated cells;
even in some of the isolates was below basal levels. This
demonstrates its role in cytoadherence and suggests the
participation of other endothelial receptors, such as hya-
luronic acid (HA) and chondroitin sulphate A (CSA).
Plasmodium vivax adherence to ICAM-1 receptor has
already been suggest by Carvalho et al., who demonstrated
a significantly higher Pv-iEs adherence to CHO ICAM-1
transfected cells in comparison to mock CHO. The find-
ings by Bernabeu et al. indicate the involvement of VIR-
14 protein in ICAM-1 cytoadherence [18].
Collectively, this study reinforces the recent findings
about P. vivax ability to cytoadhere to endothelial cells
and highlights the importance of ICAM-1 endothelial
receptors in this phenomenon.Competing interests
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